Directors' Dealings

RNS Number : 5977B

hVIVO plc

05 April 2017

 

For immediate release 7.00am: 5 April 2017

HVIVO PLC

("hVIVO" or the "Company")

 

Directors' Dealings

hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that application has been made to AIM for the admission of 15,633 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jaime Ellertson (Non-Executive Chairman) and Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of their letters of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Ellertson and Mr Winschel had entered into binding commitments to purchase $20,000 and £4,000 of hVIVO plc new ordinary shares respectively per quarter. The New Ordinary Shares represent their investments for the quarter ended 31 March 2017. On 4 April 2017, Mr Ellertson invested in an additional 12,508 ordinary shares and Mr Winschel invested in an additional 3,125 ordinary shares, at a price of 128.0 pence per share.

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 78,129,308 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 7 April 2017.  Following Admission, Mr Ellertson and Mr Winschel will be interested in a total of 77,662 and 40,315 ordinary shares of 5.0p in the Company respectively, each representing less than 0.1% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Jaime Ellertson and Jim Winschel
2	Reason for the notification
a)	Position/ status	Non-Executive Chairman and Non-Executive Director
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each  GB00B6ZM0X53
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Director Price (p) Volume Jaime Ellertson 128.0 12,508 Jim Winschel 128.0 3,125
e)	Aggregated information - Aggregated volume - Price - Aggregated total	15,633 128.0p £20,010.24
f)	Date of the transaction	4 April 2017
g)	Place of the transaction	London Stock Exchange, AIM

For further information please contact:

hVIVO plc                                                                                          [phone]

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries                                                      [phone] / [phone]

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited                                                                      [phone]

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases.  Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health.  Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

 

END

 

 

DSHUGUMGCUPMPGC